Clinical Trial Update: Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial reports long-term reinfection rates after second-line therapy for Helicobacter pylori. It compares bismuth-containing quadruple ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Helicobacter Pylori Infection

Drugs mentioned

• Bismuth-containing quadruple therapy (second-line regimen)
• Moxifloxacin-based triple therapy

Snippet

Sponsor: Seoul National University Bundang Hospital | Conditions: Helicobacter Infections | Phase 4 | Status: COMPLETED